A detailed history of Silverarc Capital Management, LLC transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Silverarc Capital Management, LLC holds 574,558 shares of KALV stock, worth $5.15 Million. This represents 1.66% of its overall portfolio holdings.

Number of Shares
574,558
Previous 560,883 2.44%
Holding current value
$5.15 Million
Previous $6.61 Million 0.7%
% of portfolio
1.66%
Previous 1.87%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$9.46 - $15.39 $129,365 - $210,458
13,675 Added 2.44%
574,558 $6.65 Million
Q2 2024

Aug 14, 2024

SELL
$10.35 - $12.49 $3,105 - $3,747
-300 Reduced 0.05%
560,883 $6.61 Million
Q1 2024

May 14, 2024

BUY
$11.07 - $16.04 $4.98 Million - $7.21 Million
449,449 Added 402.25%
561,183 $6.66 Million
Q4 2023

Feb 14, 2024

SELL
$7.58 - $12.25 $888,376 - $1.44 Million
-117,200 Reduced 51.19%
111,734 $1.37 Million
Q3 2023

Nov 13, 2023

SELL
$8.95 - $11.35 $4.4 Million - $5.58 Million
-491,574 Reduced 68.23%
228,934 $2.2 Million
Q2 2023

Aug 14, 2023

SELL
$7.73 - $10.57 $23,468 - $32,090
-3,036 Reduced 0.42%
720,508 $6.48 Million
Q1 2023

May 15, 2023

BUY
$6.3 - $8.39 $4.56 Million - $6.07 Million
723,544 New
723,544 $5.69 Million
Q3 2021

Nov 15, 2021

SELL
$17.11 - $24.49 $254,631 - $364,460
-14,882 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$23.12 - $29.91 $811,928 - $1.05 Million
-35,118 Reduced 70.24%
14,882 $357,000
Q1 2021

May 18, 2021

BUY
$14.69 - $42.57 $734,500 - $2.13 Million
50,000 New
50,000 $1.29 Million

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $220M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.